Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $189000.0.

  • TScan Therapeutics' Other Accumulated Expenses fell 2379.03% to $189000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $189000.0, marking a year-over-year decrease of 2379.03%. This contributed to the annual value of $76000.0 for FY2024, which is 8211.76% down from last year.
  • TScan Therapeutics' Other Accumulated Expenses amounted to $189000.0 in Q3 2025, which was down 2379.03% from $190000.0 recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Other Accumulated Expenses peaked at $1.3 million during Q3 2022, and registered a low of $76000.0 during Q4 2024.
  • For the 5-year period, TScan Therapeutics' Other Accumulated Expenses averaged around $452277.8, with its median value being $426000.0 (2023).
  • In the last 5 years, TScan Therapeutics' Other Accumulated Expenses surged by 66666.67% in 2021 and then tumbled by 8211.76% in 2024.
  • Over the past 5 years, TScan Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.0 million in 2021, then plummeted by 57.41% to $431000.0 in 2022, then dropped by 1.39% to $425000.0 in 2023, then tumbled by 82.12% to $76000.0 in 2024, then soared by 148.68% to $189000.0 in 2025.
  • Its Other Accumulated Expenses stands at $189000.0 for Q3 2025, versus $190000.0 for Q2 2025 and $196000.0 for Q1 2025.